Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
Key facts
- Where
- Ann Arbor, Atlanta, Boston, Chicago, Columbus, Covington, Indianapolis, Milwaukee, New York, Philadelphia, Phoenix, Portland, Rochester, and St Louis, United StatesSee the 15 sites
Where in United States
- University of MichiganAnn Arbor, United StatesNo longer taking part
- Emory University SchoolAtlanta, United StatesNo longer taking part
- Massachusetts General HospitalBoston, United StatesNo longer taking part
- Northwestern UniversityChicago, United StatesNo longer taking part
- Endocrinology Research Associates, Inc.Columbus, United StatesNo longer taking part
- St Elizabeth PhysiciansCovington, United StatesNo longer taking part
- Indiana University Schl-medIndianapolis, United StatesNo longer taking part
- Froedtert HospitalMilwaukee, United StatesNo longer taking part
- Memorial Sloan-Kettering Cancer Center (Mskcc) - New YorkNew York, United StatesNo longer taking part
- NYU Grossman School of MedicineNew York, United StatesNo longer taking part
- University of Pennsylvania Medical CenterPhiladelphia, United StatesNo longer taking part
- Barrow Neurological InstitutePhoenix, United StatesNo longer taking part
- Oregon Health and Science UniversityPortland, United StatesNo longer taking part
- Mayo Clinic - RochesterRochester, United StatesNo longer taking part
- Washington University School of MedicineSt Louis, United StatesNo longer taking part
Trial details
- Who runs it
- RECORDATI GROUP
- Trial code
- NCT05382156
- Record updated
- 20 November 2025
- Original description
This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's SyndromeRead full original descriptionShow less
A Non-interventional Study to Assess the Long-term Safety and Efficacy of Osilodrostat in Patients With Endogenous Cushing's Syndrome
This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome
Inclusion: Written informed consent obtained prior to registration of any patient data; Male or female patients aged 18 years or older with endogenous CS treated with osilodrostat. Treatment with osilodrostat can either be initiated at the first visit of the study or can have been initiated before screening.
Exclusion: Patients participating in an interventional clinical trial with an investigational drug; Patients with exogenous CS; Patients with Pseudo CS.